Poly(ethylene glycol)-modified zirconium phosphate nanoplatelets for improved doxorubicin delivery
| Autor: | Jorge L. Colón, Magaly Martínez, Abraham Clearfield, Vladimir I. Bakhmutov, Julissa González-Villegas, Aileen M. Garcia-Vargas, Yuwei Kan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Biocompatibility
Inorganic chemistry Nanoparticle macromolecular substances 02 engineering and technology 010402 general chemistry 01 natural sciences Inorganic Chemistry chemistry.chemical_compound polycyclic compounds Materials Chemistry medicine Doxorubicin Physical and Theoretical Chemistry Cytotoxicity technology industry and agriculture 021001 nanoscience & nanotechnology 0104 chemical sciences carbohydrates (lipids) chemistry Zirconium phosphate Drug delivery Surface modification 0210 nano-technology Ethylene glycol Nuclear chemistry medicine.drug |
| Zdroj: | Inorganica Chimica Acta. 468:270-279 |
| ISSN: | 0020-1693 |
| Popis: | Surface modification of doxorubicin (DOX) intercalated zirconium phosphate (ZrP) nanoparticles (DOX@ZrP) is proposed to improve the potential of this drug delivery system for cancer therapy. The surface of DOX@ZrP nanoparticles was modified with an amorphous layer of Zr(IV) followed by modification with monomethyl-poly(ethylene glycol)-monophosphate (m-PEG-PO3) as a feature to increase the DOX@ZrP biocompatibility. 31P{1H}MAS NMR data shows a new peak at −26 ppm corresponding to the PO43− groups coordinated with Zr(IV) on the surface. Initial MTS cell viability assay reveals that m-PEG-PO3/Zr(IV)/DOX@ZrP exhibits ∼20% higher cytotoxicity than free DOX and the other ZrP materials when human prostate cancer PC3 cells are exposed for 48 h. m-PEG-PO3 polymer coating of DOX@ZrP nanoparticles promise to have a strong impact on the targeting, distribution and degradation of the nanoparticles under physiological environment that should result in a more efficient chemotherapy agent than free doxorubicin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect